Molecure Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Marcin Szumowski
Chief executive officer
zł367.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.6% |
| Management average tenure | 5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO
Marcin Szumowski
Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | zł367.21k | 0.57% € 206.6k | |
| Chief Scientific Officer & Member of Management Board | 4yrs | zł367.21k | 0.092% € 33.3k | |
| Chief Medical Officer & Member of Management Board | 1.3yrs | zł122.47k | no data | |
| HR Director | 6yrs | zł271.21k | 0.028% € 10.2k | |
| Co-Founder & VP of Research Chemistry | 14yrs | zł500.00k | no data | |
| Co-Founder & Head of Medicinal Chemistry | no data | no data | no data | |
| Finance Director | 1yr | no data | no data | |
| Head of CMC | 6yrs | no data | no data |
Experienced Management: 1B1's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Vice Chairman of the Supervisory Board | 6yrs | zł129.06k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Supervisory Board | 4yrs | zł154.87k | 0.049% € 17.6k | |
| Independent Member of the Supervisory Board | 4yrs | zł129.06k | no data | |
| Member of the Supervisory Board | 2.5yrs | zł103.25k | no data | |
| Independent Member of the Supervisory Board | 3.6yrs | zł129.06k | no data |
Experienced Board: 1B1's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/27 17:21 |
| End of Day Share Price | 2026/01/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molecure S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Marcin Nowak | Ipopema Securities S.A. |